Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 272-712-1 | CAS number: 68909-77-3 The residuum from the reaction of diethylene glycol and ammonia. It consists predominantly of morpholine-based derivatives such as [(aminoethoxy)ethyl]morpholine, [(hydroxyethoxy)ethyl]morpholine, 3-morpholinone, and 4,4'-(oxydi-2,1-ethanediyl)bis[morpholine].
Acute Toxicity: other routes
Administrative data
- Endpoint:
- acute toxicity: other routes
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study report meets generally acceptable scientific principles
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 969
- Report date:
- 1969
Materials and methods
- Principles of method if other than guideline:
- Study to determine the acute i.p. toxicity ot the test substance in mice
- GLP compliance:
- no
Test material
- Reference substance name:
- Ethanol, 2,2'-oxybis-, reaction products with ammonia, morpholine derivs. residues
- EC Number:
- 272-712-1
- EC Name:
- Ethanol, 2,2'-oxybis-, reaction products with ammonia, morpholine derivs. residues
- Cas Number:
- 68909-77-3
- Molecular formula:
- Not applicable (UVCB)
- IUPAC Name:
- 2-(2-hydroxyethoxy)ethan-1-ol; 2-[1-(morpholin-4-yl)ethoxy]ethan-1-amine; 2-{2-[bis(2-hydroxyethyl)amino]ethoxy}ethan-1-ol; 4-{2-[2-(morpholin-4-yl)ethoxy]ethyl}morpholine; morpholin-3-one
- Details on test material:
- - Name of test material (as cited in study report): Morpholin-Rueckstand (morpholin remainder)
- Substance type: remainder mixture
- Physical state: liquid
- Analytical purity: no data
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- not specified
- Sex:
- male/female
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- water
- Details on exposure:
- 2%-20%
- Doses:
- 200-1600 µL/kg (=ca. 212-1700 mg/kg; calculated with a density of 1.06 g/mL)
- No. of animals per sex per dose:
- 10
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 742 mg/kg bw
- Remarks on result:
- other: original data: ca. 0.7 mL/kg bw
- Mortality:
- no mortality up to 400 µL/kg bw
500 µL/kg bw: 2/20
640 µL/kg bw: 3/20
800 and 1600 µL/kg bw: 20/20 - Clinical signs:
- 800 and 1600 µL/kg bw: directly after injection tremor, convulsion, stretching, crying, sunken flanks, high stepping and slightly staggering gait, avoidance of abdominal position, agitation, closed eye lids; intense stretching convulsions in agony
<= 640 µL/kg bw: symptoms as decribed for higher doses but in weaker extension; reversible within at least 6 days - Body weight:
- not measured at study termination
- Gross pathology:
- Animals that died: Intestines filled with bloody liquids, lobular pataatern visible;4* intraabdominal adhesions
Sacrificed animals: in most of the animals intrabdominal adhesions, 12* truncated liver edges
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
